|
Represents a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders TORONTO, March 24, 2021 /CNW/ - Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), today announced that its wholly-owned subsidiary, PharmaTher Inc. ("PharmaTher"), a psychedelics biotech company, has entered into a sponsored research agreement with The Queen's University of Belfast ("QUB") for the development of a patented hydrogel-forming microneedle ("MN") patch to deliver ketamine and the PharmaTher's proprietary ketamine formulation, KETABET™". This advance represents a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders.
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce the appointment of Dr. Maurizio Fava, MD, as a scientific and clinical advisor for PharmaTher’s clinical research initiatives with KETABET™”, a patented combination formulation of FDA-approved ketamine and betaine, as a potential next-generation treatment for major depressive disorder.
TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive license agreement with The University of Kansas for the development and commercialization for the intellectual property of ketamine in the treatment amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig's disease.
TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce today that its common shares are now eligible for electronic clearing and settlement through The Depository Trust Company ("DTC") in the United States. In addition to trading in the United States on the OTCQB Venture Market under the symbol “PHRRF”, the Company’s common shares continue to trade on the Canadian Securities Exchange under “PHRM”.
|
RSS Feed
3/24/2021